Background-Sulindac is a non-steroidal anti-inflammatory drug which induces regression of colonic polyps in patients with familial adenomatous polyposis. Animal and in vitro studies have shown that both the sulphide metabolite of sulindac, which is able to inhibit cyclo-oxy-
dac sulphone (control: 37 Sulindac (cis-5-fluoro-2-methyl-l-[p-(methylsulphinyl) benzylidene] indene-3-acetic acid) is a non-steroidal anti-inflammatory (NSAID) drug which had primarily been used in the treatment of rheumatic diseases. It acts as a competitive inhibitor of cyclo-oxygenase, a key enzyme in the prostaglandin biosynthetic pathway.1
In 1983 Waddell and Loughry first reported that sulindac induced the regression of rectal polyps in patients with familial adenomatous polyposis (FAP) who had undergone subtotal colectomy and ileorectal anastomosis.2 This initial finding has subsequently been confirmed by several other investigators who have shown that sulindac causes a reduction in the number and size of polyps in patients with FAP, both in the intact colon and in the rectum after colectomy.3-6 Sulindac is ingested orally as an inactive prodrug. It is reduced to its active form, sulindac sulphide, by the action of colonic bacteria resulting in high levels of the active agent in the colon.7 The observed effect of sulindac on polyp growth is reversible: recurrence is observed on stopping treatment.
Despite its efficacy in inducing polyp regression, the role of sulindac in reducing the risk of colorectal carcinoma is not yet established. There have been reports of the development of rectal cancer in patients being treated with this agent, despite regular endoscopic surveillance.8 9 In one study, reduced prostaglandin biosynthesis was observed in colonic mucosal biopsy specimens from FAP patients on sulindac therapy.6 Despite this observation, the mechanism by which sulindac inhibits the development of polyps in FAP remains unclear. Similar inhibition of polyp development has not been seen with other NSAIDs such as indomethacin,10 and studies of non-FAP patients with colonic polyps have also failed to show a reduction in polyp number or size after sulindac treatment, although only small numbers of patients have been studied.'1 12 Evidence that the observed effect of sulindac may be mediated via a prostaglandin-independent mechanism is provided by studies which have shown a lack of correlation between a reduction in colonic prostaglandin biosynthesis and the inhibition of carcinogen induced colonic tumours.13 14 In addition, sulindac sulphone, a metabolite of sulindac which lacks the cyclo-oxygenase inhibitory activity of the active form of the drug, has been shown to have a similar effect to that of the active form of the drug, sulindac sulphide, both in vitro and in a rat model of colonic carcinogenesis. '5 16 In view of the apparent specificity of sulindac in FAP patients and the possibility that at least some of its effect is mediated via a prostaglandin-independent mechanism, we have examined the effect of sulindac sulphide and sulindac sulphone on APC mRNA in cultured colonic cells.
The APC gene is a tumour suppressor gene which is mutated in the germline of patients with FAP, and also in a significant number of sporadic colonic neoplasms.17 18 In the vast majority of cases, the mutation is inactivating, and results in the formation of a truncated mutant protein. The APC protein is thought to have a role in cell adhesion, as the wildtype product has been shown to associate with the cell adhesion proteins 3-catenin and E-cadherin, and is able to regulate intracellular levels of ,3-catenin.19 21 tumour formation in a rat. 30 Conversely, Craven and DeRubertis administered aspirin to rats in doses sufficient to suppress colonic PGE2 production by 95%, without observing a reduction in 1,2-DMH-induced colonic carcinoma in a rat model. '3 The effect of sulindac on cell proliferation has been assessed in several clinical studies. Labayle et al measured Ki67 indices in six patients who had a significant reduction in polyp numbers while being treated with sulindac, and failed to detect any difference in the measurement of cell cycling. 4 Nugent et al, in a controlled trial of 24 patients with rectal polyps following ileorectal anastomosis, showed a significant reduction in polyp size and number, which was accompanied by a reduction in epithelial proliferation as measured by incorporation of 5-bromo-2'-deoxyuridine. 5 Others have shown a reduction in colonic cell proliferation in vitro in response to sulindac treatment.3' Of note, a similar reduction in cell proliferation was also observed after treatment with sulindac sulphone, suggesting that this effect occurs independently of the prostaglandin biosynthetic pathway.
The ability of colonic mucosa to synthesise various prostaglandins has been demonstrated in a number of studies.32 33 Higher levels of prostaglandins, particularly PGE2, have been measured in colonic tumours than in surrounding normal mucosa.32 34 Cell lines derived from human colonic tumours do not always produce detectable quantities of prostaglandins,35 however, the cell line used in this study, LIM 1215, produced sufficient PGE2 to be detected by radioimmunoassay, and we showed a significant reduction in PGE2 levels after treatment with sulindac sulphide. The metabolite sulindac sulphone failed to suppress PGE2 levels in this cell line, confirming the fact that it lacks cyclo-oxygenase inhibitory activity. Despite this lack of effect on prostaglandin production, sulindac sulphone had a similar effect to that of the active form of the drug in increasing APC mRNA levels.
Sulindac sulphide has been shown to inhibit the expression of several intermediate early genes, including c-myc, c-fos, and jun-B, whose expression was induced by TGFox stimulation in a rat model.36 Both indomethacin and sulindac sulphide inhibited the expression of the rat homologue of the cyclo-oxygenase-2 (COX-2) gene, and they have also been shown to reduce prostaglandin production in this model.37 Despite these observations, the effect on the expression of the intermediate early genes was seen only with sulindac sulphide, and was not observed after treatment with indomethacin. Nuclear run-on assays showed that the inhibition occurred at the level of transcription, and suggested that sulindac sulphide has a direct effect on the expression of these genes.
Several other mechanisms by which sulindac could have its effect have been proposed, including the suppression of ornithine decarboxylase activity, alteration of cell cycle kinetics, and induction of apoptosis.'6 38 observed in the LIM 1215 cell line examined in this study. A reduction in cell numbers and cell proliferation occurred after treatment with both agents at doses of 50 and 100 ,uM, with the effect of sulindac sulphide being more marked than for sulindac sulphone. Treatment with each agent at the 10 ,uM concentration did not result in a significant reduction in cell number or proliferation.
In summary, this study has confirmed reports that both the sulphide and sulphone metabolites of sulindac are able to inhibit the growth of colonic cells in culture, and has also demonstrated that this effect is not dependent upon a reduction in PGE2 synthesis. In addition, it has been shown that both agents are able to increase the expression of APC mRNA as measured by QRT PCR. The finding that these drugs have an effect on APC mRNA is consistent with the evidence from clinical studies of an apparently specific effect of sulindac on polyps in FAP patients when compared to sporadic polyps in non-FAP patients.'1 12
In individuals with FAP, the inactivating germline mutation causes a reduction in the amount of wild-type APC protein produced, which might possibly be below a threshold necessary to prevent neoplasia.42 One possible explanation suggested by these results is that an increase in the expression of APC mRNA induced by sulindac could increase the amount of normal gene product above the threshold required to maintain growth control.
It has been suggested that the APC gene may act via a dominant negative mechanism, in view of the finding that mutant and wildtype APC proteins are able to associate in vivo.43 Even if this is the mechanism by which APC gene mutations exert their effects, it is still possible that factors which increase the expression of APC mRNA might affect the function of the gene. This could occur if there were a proportionately greater increase in the quantity of normal APC protein in relation to the mutant product. Smith et al have shown that certain forms of truncated APC are expressed at much lower levels than the full length products, suggesting that mutant forms of the protein or mRNA may be less stable than the normal gene product.44 Studies of the human 3-globin gene have shown that the presence of nonsense mutations can result in destabilisation of the full-length mRNA and the production of degradation products.45 It is thus possible that the increase in APC mRNA produced in response to sulindac treatment could result in a relative increase in the quantity of the normal APC protein as compared to the abnormal gene product. We speculate that this may in turn reduce the proportion of the full length APC sequestered by the mutant protein and restore some of the tumour suppressing function of the gene.
Sulindac sulphide and sulindac sulphone are able to inhibit the growth of colonic cells both in vitro and in animal models. The sulphide form of the drug has also been shown to be effective in causing regression of polyps in patients with FAP. Several different mechanisms have been proposed to account for the action of these agents in preventing colonic neoplasia, including the inhibition of cyclooxygenase activity, alteration of cell cycle kinetics, the inhibition of intermediate early gene expression, and the induction of apoptosis. The present study suggests that another possible mode of action is related to an increase in colonic APC mRNA. It is likely that a combination of these different mechanisms, some of which may be inter-related, will ultimately be shown to mediate the effects of sulindac on the colonic epithelium.
